Related Experiment Video
Updated: Jan 19, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
Persistent heart failure following melphalan and fludarabine conditioning.
Gisella Newbery1, Neiberg de Alcantara Lima2, Livia Andrade Gurgel3
1Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA.
Chemotherapy drugs melphalan and fludarabine rarely cause heart issues alone. However, this case shows their combination can lead to severe heart failure after bone marrow transplant.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- Cancer treatments like chemotherapy and radiotherapy improve survival but can cause severe side effects.
- Cardiotoxicity, including heart failure, is a critical concern, sometimes outweighing cancer risks.
- Melphalan and fludarabine are chemotherapy agents not typically linked to heart damage.
Related Concept Videos
07:49A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure VI: Adjunct Therapies
07:35Gene Transfer for Ischemic Heart Failure in a Preclinical Model

